Results 81 to 90 of about 17,271 (194)
Purpose The real-world effectiveness and safety of abiraterone or enzalutamide in the Asian population with metastatic castration-resistant prostate cancer (mCRPC) remains unclear.
Wen-Kuan Huang +11 more
doaj +1 more source
Abiraterone is approved in combination with prednisone and a luteinizing hormone-releasing hormone (LHRH) analogue for castration-resistant prostate cancer (CPRC) patients progressing in the form of previa [1] or after treatment with docetaxel [2]. CPRC patients treated with abiraterone should take four tablets on an empty stomach one hour before ...
Barreiro, Diego Martin +1 more
openaire +2 more sources
We report two cases of metastatic castration‐resistant prostate cancer (mCRPC) with long‐term survival following treatment with abiraterone. Despite the generally temporary efficacy of abiraterone, both patients remained progression‐free for over 5 years,
Minami Une +5 more
doaj +1 more source
Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
Chrystia M Zobniw,1 Alanna Causebrook,2 Mei Ka Fong1 1Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY, USA; 2School of Pharmacy, Lake Erie College of Osteopathic Medicine, Erie, PA, USA Abstract: Prostate cancer remains the most ...
Causebrook A, Fong MK, Zobniw CM
core
Metastatic castration-resistant prostate cancer (mCRPC) with visceral involvement requires new, effective and safe treatments after chemotherapy failure.
Laura Dupuy +2 more
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration and/or an antiandrogen.
Taylor, AE +14 more
core +1 more source
Pietro Castellan,1 Michele Marchioni,2 Roberto Castellucci,1 Piergustavo De Francesco,2 Romina Iantorno,1 Luigi Schips,1,2 Luca Cindolo1 1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Urology, University “G.
Marchioni M +6 more
core
188 Background: Abiraterone or enzalutamide are licensed for use post-docetaxel in metastatic castrate resistant prostate cancer (mCRPC). Both target the androgen receptor signalling pathway. There is little information describing their sequential use.
Omi Parikh +2 more
core +1 more source
Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis
Background Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined.
Xiaolei Zhu, Shenhong Wu
doaj +1 more source

